Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study

Patricia Pozo-Rosicha Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain;b Headache and Neurological Pain Research Group, Vall d’Hebron Institute of Research (VHIR), Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain

Holland C. Detkec Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]

https://orcid.org/0000-0002-1316-6064

Shufang Wangc Eli Lilly and Company, Indianapolis, IN, USA;f Now at Sarepta Therapeutics, Cambridge, MA, USA

David Doležild Prague Headache Center, DADO MEDICAL s.r.o, Prague, Czech Republic

Lily Q. Lic Eli Lilly and Company, Indianapolis, IN, USA

Sheena K. Aurorac Eli Lilly and Company, Indianapolis, IN, USA;g Now at Impel NeuroPharma, Seattle, WA, USA

Uwe Reutere Department of Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany

show all

Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date